Ceftazidime
Ceftazidime is categorized as a third-generation cephalosporin which show a broad spectrum of in vitro activity against both Gram-positive and Gram-negative aerobic bacteria, including Pseudomonas aeruginosa (P. aeruginosa). In fact, ceftazidime is by far the most active cephalosporin available against P. aeruginosa in vitro, but it is less active against Staphylococcus aureus (S. aureus) than first and second generation cephalosporins. Also, ceftazidime is particularly active against most Enterobacteriaceae, including β-lactamase-positive strains, since it is highly resistant to hydrolysis induced by β-Iactamases.?
Reference:
1. Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 1985, 29(2): 105-161.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 546.58 |
| Cas No. | 72558-82-8 |
| Formula | C22H22N6O7S2 |
| Solubility | ≥21.25 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| Chemical Name | 2-(((Z)-((Z)-2-(((6R,7R)-2-carboxy-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl)imino)-2-hydroxy-1-(2-imino-2,3-dihydrothiazol-4-yl)ethylidene)amino)oxy)-2-methylpropanoate |
| SDF | Download SDF |
| Canonical SMILES | CC(C([O-])=O)(O/N=C(\C(O)=N\[C@]([C@]1([H])N2C(C(O)=O)=C(CS1)C[N+]3=CC=CC=C3)([H])C2=O)C(N4)=CSC4=N)C |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
Pseudomonas aeruginosa |
|
Preparation method |
The solubility of this compound in DMSO is ≥ 21.25mg/mL . General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
32 mg/L |
|
Applications |
90% of tested strains of P. aeruginosa including β-lactamase-positive, as well as cefsulodin-, piperacillin-, carbenicillin-or aminoglycoside-resistant isolates, are sensitive or moderately sensitive to ceftazidime (MIC90 0.5 to 32 mg/L). Ceftazidime is also active in vitro against P. cepacia, P. alcali genes, P. putida and VA-1 (P. picketti), but some other Pseudomonas species are resistant. |
| Animal experiment [1]: | |
|
Animal models |
Patients with bacteriologically confirmed pneumonia or bronchitis |
|
Dosage form |
3 to 6 g/day as 2 to 4 divided doses |
|
Application |
In patients with bacteriologically confirmed pneumonia or bronchitis, usually complicated by underlying diseases, mean clinical response rates (cured) of 51 to 88% have been reported in various comparative studies following treatment with ceftazidime (3 to 6 g/day as 2 to 4 divided doses). Mean clinical response rates of 53 to 88% were reported for patients in the comparative groups (cefamandole 1.5g 8-hourly or 1g 6-hourly, cefazolin 1.5g plus tobramycin 1.7 mg/kg 8-hourly, or ticarcillin 3g 4-hourly plus tobramycin 1.5 mg/kg 8-hourly). |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105-61. Review. PubMed PMID: 3884319. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
